A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

Trial Profile

A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top